PD-1/PD-L1 Pathway Study on Septic Patients

NCT ID: NCT01161745

Last Updated: 2010-07-14

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 39 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2008-12-31
• Study Completion Date: 2010-04-30

Brief Summary

The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.

Detailed Description

First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls.

Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC function and apoptosis by flow cytometry.

Then, compare with healthy controls and find the differences.

Conditions

Sepsis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Eligibility Criteria

Inclusion Criteria

• patients who develop sepsis

Exclusion Criteria

• patients with cirrhosis or renal dysfunction
• patients with dyscrasia
• patients with autoimmunity diseases
• patients with severe cardiac and pulmonary diseases
• patients with hematological diseases
• patients with diabetes mellitus
• patients with malignant tumors

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Natural Science Foundation of China

OTHER_GOV

Sponsor Role: collaborator

Changhai Hospital

OTHER

Sponsor Role: lead

Responsible Party

Department of Anesthesiology and Intensive Care Unit

Principal Investigators

Xiao-ming Deng, doctor

Role: PRINCIPAL_INVESTIGATOR

Changhai Hospital, the Second Military Medical University

Other Identifiers

ANETHDEPT-001

Identifier Type: -

Identifier Source: org_study_id